Show simple item record

dc.contributor.authorDwyer, Róisín M.
dc.contributor.authorRyan, James
dc.contributor.authorHavelin, Ronan J.
dc.contributor.authorMorris, John C.
dc.contributor.authorMiller, Brian W.
dc.contributor.authorLiu, Zhonglin
dc.contributor.authorFlavin, Richard
dc.contributor.authorO'Flatharta, Cathal
dc.contributor.authorFoley, Mark J.
dc.contributor.authorBarrett, Harrison H
dc.contributor.authorMurphy, J. Mary
dc.contributor.authorBarry, Frank P
dc.contributor.authorO'Brien, Timothy
dc.contributor.authorKerin, Michael J.
dc.identifier.citationDwyer RM;Ryan J;Havelin RJ;Morris JC;Miller BW;Liu Z;Flavin R;O'Flatharta C;Foley MJ;Barrett HH;Murphy JM;Barry FP;O'Brien T;Kerin MJ; (2011) 'Mesenchymal Stem Cell-mediated delivery of the sodium iodide symporter supports radionuclide imaging and treatment of breast cancer'. Stem Cells (Dayton, Ohio), 29 (7).en_IE
dc.description.abstractMesenchymal Stem Cells (MSCs) migrate specifically to tumors in vivo, and coupled with their capacity to bypass immune surveillance, are attractive vehicles for tumor-targeted delivery of therapeutic agents. This study aimed to introduce MSC-mediated expression of the sodium iodide symporter (NIS) for imaging and therapy of breast cancer. Tumor bearing animals received an intravenous or intratumoral injection of NIS expressing MSCs (MSC-NIS), followed by (99m) Technetium pertechnetate imaging 3-14 days later using a BazookaSPECT ¿-camera. Tissue was harvested for analysis of human NIS (hNIS) expression by relative quantitative-polymerase chain reaction. Therapy animals received an i.p. injection of (131) I or saline 14 days after injection of MSC-NIS, and tumor volume was monitored for 8 weeks. After injection of MSC-NIS, BazookaSPECT imaging revealed an image of animal intestines and chest area at day 3, along with a visible weak tumor image. By day 14, the tumor was visible with a significant reduction in radionuclide accumulation in nontarget tissue observed. hNIS gene expression was detected in the intestines, heart, lungs, and tumors at early time points but later depleted in nontarget tissues and persisted at the tumor site. Based on imaging/biodistribution data, animals received a therapeutic dose of (131) I 14 days after MSC-NIS injection. This resulted in a significant reduction in tumor growth (mean ± SEM, 236 ± 62 mm(3) vs. 665 ± 204 mm(3) in controls). The ability to track MSC migration and transgene expression noninvasively in real time before therapy is a major advantage to this strategy. This promising data supports the feasibility of this approach as a novel therapy for breast cancer.en_IE
dc.description.sponsorshipWe thank Martina Harte for assistance with virus amplification; Georgina Shaw for MSC isolation; Zdzislaw Zuchora for assistance with radionuclides; Emer Hennessy, Catherine Curran, and Charles McHale for technical support. This work was supported by Health Research Board of Ireland (RP2007/197; to R.M.D.); Cancer Research Ireland (CRI07/DWY; to J.R.); Science Foundation Ireland (to C.O.F., T.O.B., F.P.B., and J.M.M.); National Breast Cancer Research Institute; and National Institute for Biomedical Imaging and Bioengineering (P41‐EB002035; to the Center for Gamma‐Ray Imaging).en_IE
dc.publisherAlphaMed Pressen_IE
dc.relation.ispartofStem Cells (Dayton, Ohio)en
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Ireland
dc.subjectMesenchymal Stem Cell‐Mediated Deliveryen_IE
dc.subjectSodium Iodide Symporteren_IE
dc.subjectRadionuclide Imagingen_IE
dc.subjectBreast Canceren_IE
dc.titleMesenchymal stem cell-mediated delivery of the sodium iodide symporter supports radionuclide imaging and treatment of breast canceren_IE
dc.local.contactRóisín Dwyer, Surgery, Nui Galway. 3008 Email:

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Ireland
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland